ME03419B - Supstituirani spojevi dihidroizokinolinona - Google Patents

Supstituirani spojevi dihidroizokinolinona

Info

Publication number
ME03419B
ME03419B MEP-2019-85A MEP201985A ME03419B ME 03419 B ME03419 B ME 03419B ME P201985 A MEP201985 A ME P201985A ME 03419 B ME03419 B ME 03419B
Authority
ME
Montenegro
Prior art keywords
compounds
substituted
substituted dihydroisoquinolinone
dihydroisoquinolinone compounds
dihydroisoquinolinone
Prior art date
Application number
MEP-2019-85A
Other languages
German (de)
English (en)
French (fr)
Inventor
Michael Raymond Collins
Robert Steven Kania
Pei-Pei Kung
Robert Arnold Kumpf
Daniel Tyler Richter
Scott Channing Sutton
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ME03419B publication Critical patent/ME03419B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MEP-2019-85A 2014-06-17 2015-06-05 Supstituirani spojevi dihidroizokinolinona ME03419B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462013410P 2014-06-17 2014-06-17
US201562156533P 2015-05-04 2015-05-04
EP15730290.2A EP3157915B1 (en) 2014-06-17 2015-06-05 Substituted dihydroisoquinolinone compounds
PCT/IB2015/054272 WO2015193765A1 (en) 2014-06-17 2015-06-05 Substituted dihydroisoquinolinone compounds

Publications (1)

Publication Number Publication Date
ME03419B true ME03419B (me) 2020-01-20

Family

ID=53434412

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-85A ME03419B (me) 2014-06-17 2015-06-05 Supstituirani spojevi dihidroizokinolinona

Country Status (40)

Country Link
US (4) US9481666B2 (me)
EP (2) EP3521285A1 (me)
JP (1) JP6152495B1 (me)
KR (1) KR101877187B1 (me)
CN (1) CN107207464B (me)
AP (1) AP2016009605A0 (me)
AU (1) AU2015275826B2 (me)
BR (1) BR112016029612B1 (me)
CA (1) CA2894298C (me)
CL (1) CL2016003246A1 (me)
CR (2) CR20200484A (me)
CU (1) CU24408B1 (me)
CY (1) CY1121706T1 (me)
DK (1) DK3157915T3 (me)
EA (1) EA031892B1 (me)
ES (1) ES2721031T3 (me)
GE (2) GEP20186933B (me)
HR (1) HRP20190604T1 (me)
HU (1) HUE042964T2 (me)
IL (1) IL248991B (me)
LT (1) LT3157915T (me)
MA (1) MA40225B1 (me)
MD (1) MD4820C1 (me)
ME (1) ME03419B (me)
MX (1) MX2016016764A (me)
MY (1) MY185765A (me)
NZ (1) NZ726108A (me)
PE (1) PE20161552A1 (me)
PH (1) PH12016502378A1 (me)
PL (1) PL3157915T3 (me)
PT (1) PT3157915T (me)
RS (1) RS58632B1 (me)
SG (1) SG11201609386YA (me)
SI (1) SI3157915T1 (me)
SV (1) SV2016005333A (me)
TN (1) TN2016000529A1 (me)
TW (1) TWI561516B (me)
UA (1) UA118380C2 (me)
UY (1) UY36170A (me)
WO (1) WO2015193765A1 (me)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
TN2016000529A1 (en) 2014-06-17 2018-04-04 Pfizer Substituted dihydroisoquinolinone compounds
UY36758A (es) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
KR20190003699A (ko) 2016-05-05 2019-01-09 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2019016112A1 (en) 2017-07-17 2019-01-24 AbbVie Deutschland GmbH & Co. KG SUBSTITUTED QUINOLINE COMPOUNDS IN POSITIONS 1, 2, 3 AND 4 AS MODULATORS OF S1P
BR112020008325A2 (pt) * 2017-11-14 2020-10-20 Pfizer Inc. terapias de combinação com o inibidor de ezh2
MX2020007974A (es) 2018-01-31 2020-09-07 Mirati Therapeutics Inc Inhibidores de complejo represivo polycomb 2 (prc2).
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) * 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
WO2020086857A1 (en) * 2018-10-24 2020-04-30 Vanderbilt University Wdr5 inhibitors and modulators
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
WO2020247679A1 (en) 2019-06-04 2020-12-10 Vanderbilt University Wdr5 inhibitors and modulators
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos
WO2022018594A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Synthesis of novel intermediates for substituted 3,4-dihydroisoquinolinones
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
MX2023001603A (es) * 2020-08-13 2023-03-07 Hanmi Pharmaceutical Co Ltd Derivados de dioxoloisoquinolinona novedosos y uso de los mismos.
CN116783188A (zh) * 2020-12-11 2023-09-19 上海奕拓医药科技有限责任公司 一种二氢异喹啉酮衍生物及其应用
CN118302427A (zh) * 2021-12-02 2024-07-05 上海翰森生物医药科技有限公司 稠环类衍生物调节剂、其制备方法和应用
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
CN116239519A (zh) * 2023-02-20 2023-06-09 安徽峆一药业股份有限公司 一种(2-苄氧基-4,6-二甲基吡啶-3-基)甲醇的合成方法
WO2025064641A1 (en) * 2023-09-19 2025-03-27 Sri International Synthetic compounds comprising dihydroisoquinolinone monomers

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MX2008002207A (es) 2005-08-16 2008-03-27 Memory Pharm Corp Inhibidores de fosfodiesterasa 10.
AU2006331765A1 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2009153589A1 (en) * 2008-06-17 2009-12-23 Astrazeneca Ab Pyridine compounds
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インダゾール
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
WO2013059944A1 (en) * 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
JP6067878B2 (ja) 2012-12-21 2017-01-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft オキシトシンアゴニストとしてのペプチド
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
TN2016000529A1 (en) 2014-06-17 2018-04-04 Pfizer Substituted dihydroisoquinolinone compounds

Also Published As

Publication number Publication date
CN107207464B (zh) 2019-10-22
US20150361067A1 (en) 2015-12-17
KR101877187B1 (ko) 2018-07-10
MX2016016764A (es) 2017-04-25
UY36170A (es) 2016-01-29
PH12016502378A1 (en) 2017-02-20
SV2016005333A (es) 2017-03-06
TN2016000529A1 (en) 2018-04-04
SG11201609386YA (en) 2017-01-27
TW201609697A (zh) 2016-03-16
CA2894298C (en) 2017-04-18
CA2894298A1 (en) 2015-12-17
WO2015193765A1 (en) 2015-12-23
PE20161552A1 (es) 2017-01-11
EP3157915A1 (en) 2017-04-26
US9481666B2 (en) 2016-11-01
CN107207464A (zh) 2017-09-26
MD20160136A2 (ro) 2017-05-31
EP3157915B1 (en) 2019-02-27
CU20160180A7 (es) 2017-03-03
MD4820B1 (ro) 2022-08-31
HUE042964T2 (hu) 2019-07-29
MY185765A (en) 2021-06-06
US10570121B2 (en) 2020-02-25
MA40225A (fr) 2019-02-27
MD4820C1 (ro) 2023-03-31
IL248991A0 (en) 2017-01-31
EA201692114A1 (ru) 2017-06-30
EA031892B1 (ru) 2019-03-29
GEP20186933B (en) 2018-12-10
AP2016009605A0 (en) 2016-12-31
GEAP201814347A (en) 2018-08-10
PT3157915T (pt) 2019-05-16
DK3157915T3 (en) 2019-04-23
TWI561516B (en) 2016-12-11
AU2015275826B2 (en) 2019-05-16
UA118380C2 (uk) 2019-01-10
BR112016029612A2 (pt) 2017-08-22
JP6152495B1 (ja) 2017-06-21
LT3157915T (lt) 2019-04-25
IL248991B (en) 2020-02-27
HRP20190604T1 (hr) 2019-05-31
CR20160574A (es) 2017-02-23
PL3157915T3 (pl) 2019-07-31
CR20200484A (es) 2021-04-26
CY1121706T1 (el) 2020-07-31
US20170298048A1 (en) 2017-10-19
ES2721031T3 (es) 2019-07-26
SI3157915T1 (sl) 2019-05-31
EP3521285A1 (en) 2019-08-07
BR112016029612B1 (pt) 2021-01-19
MA40225B1 (fr) 2019-05-31
CL2016003246A1 (es) 2017-07-14
JP2017519013A (ja) 2017-07-13
US20160376254A1 (en) 2016-12-29
KR20170016493A (ko) 2017-02-13
US20190040047A1 (en) 2019-02-07
RS58632B1 (sr) 2019-05-31
AU2015275826A1 (en) 2016-11-24
CU24408B1 (es) 2019-05-03
NZ726108A (en) 2020-06-26

Similar Documents

Publication Publication Date Title
EP3720430A4 (en) BENZOCARBONYL COMPOUNDS
ME03419B (me) Supstituirani spojevi dihidroizokinolinona
HUE050732T2 (hu) Új vegyületek
LT3134402T (lt) 4-amino-imidazochinolino junginiai
MA42293A (fr) Composés antibactériens
EP3523306A4 (en) Spirocyclic compounds
PT3298027T (pt) Compostos depsipéptidos antelmínticos
BR112016029361A2 (pt) novos compostos substituídos por halogênio
EP3464336A4 (en) LINKS
DK3157926T3 (da) Organiske forbindelser
BR112016030730A2 (pt) Composto
EP3728289A4 (en) OPTIMIZED CONNECTIONS
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
HUE054351T2 (hu) Vegyületek
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
EP3310352A4 (en) CRYSTALLINE COMPOUNDS
DK3183242T3 (da) Substituerede bicykliske forbindelser
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
EP3259254A4 (en) THERAPEUTIC COMPOUNDS
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
HUE042493T2 (hu) Újfajta fuzionált imidazobenzotiazol vegyületek
BR112017002509A2 (pt) novos compostos substituídos com halogênio
LT3331885T (lt) Junginiai
MA41168A (fr) Nouveaux composés antibactériens
MA48946A (fr) Composés